JP2015532097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532097A5 JP2015532097A5 JP2015534781A JP2015534781A JP2015532097A5 JP 2015532097 A5 JP2015532097 A5 JP 2015532097A5 JP 2015534781 A JP2015534781 A JP 2015534781A JP 2015534781 A JP2015534781 A JP 2015534781A JP 2015532097 A5 JP2015532097 A5 JP 2015532097A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polynucleotide
- sequence number
- composition
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims description 87
- 239000002157 polynucleotide Substances 0.000 claims description 87
- 102000040430 polynucleotide Human genes 0.000 claims description 87
- 230000028993 immune response Effects 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 23
- 208000023275 Autoimmune disease Diseases 0.000 claims description 20
- 230000001419 dependent effect Effects 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 15
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 8
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims description 6
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 4
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 32
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000000644 isotonic solution Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 5
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707887P | 2012-09-29 | 2012-09-29 | |
| US61/707,887 | 2012-09-29 | ||
| US201361761214P | 2013-02-05 | 2013-02-05 | |
| US61/761,214 | 2013-02-05 | ||
| US13/842,861 US9228184B2 (en) | 2012-09-29 | 2013-03-15 | Human toll-like receptor inhibitors and methods of use thereof |
| US13/842,861 | 2013-03-15 | ||
| PCT/US2013/062479 WO2014052931A1 (en) | 2012-09-29 | 2013-09-27 | Human toll-like receptor inhibitors and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532097A JP2015532097A (ja) | 2015-11-09 |
| JP2015532097A5 true JP2015532097A5 (enExample) | 2016-11-10 |
| JP6395266B2 JP6395266B2 (ja) | 2018-09-26 |
Family
ID=50385792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534781A Active JP6395266B2 (ja) | 2012-09-29 | 2013-09-27 | ヒトＴｏｌｌ様受容体阻害剤およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9228184B2 (enExample) |
| EP (1) | EP2900823B1 (enExample) |
| JP (1) | JP6395266B2 (enExample) |
| CN (1) | CN104937102A (enExample) |
| AU (1) | AU2013202255B2 (enExample) |
| CA (1) | CA2886755A1 (enExample) |
| WO (1) | WO2014052931A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| TW201630606A (zh) * | 2015-01-21 | 2016-09-01 | 諾華公司 | 包含局部藥物之蓋崙（ｇａｌｅｎｉｃ）調配物 |
| EP3265098B1 (en) * | 2015-03-03 | 2025-03-26 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
| WO2017136399A1 (en) * | 2016-02-02 | 2017-08-10 | Idera Pharmaceuticals, Inc. | POTENTIATION OF mmRNA THERAPEUTICS |
| TW202320855A (zh) * | 2016-09-02 | 2023-06-01 | 美商愛羅海德製藥公司 | 標靶性配體 |
| EP3538513A1 (en) | 2016-11-11 | 2019-09-18 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| WO2019000045A1 (en) * | 2017-06-30 | 2019-01-03 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | METHOD OF TREATMENT |
| CA3144902A1 (en) | 2019-08-14 | 2022-01-19 | Andreas Thess | Rna combinations and compositions with decreased immunostimulatory properties |
| AU2020407871A1 (en) | 2019-12-20 | 2022-06-30 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof |
| JP2024513131A (ja) * | 2021-04-08 | 2024-03-21 | ハドソン インスティチュート オブ メディカル リサーチ | オリゴヌクレオチド |
| EP4590310A2 (en) | 2022-09-23 | 2025-07-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing mecp2 expression |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
| US4587329A (en) | 1984-08-17 | 1986-05-06 | The Dow Chemical Company | Dense star polymers having two dimensional molecular diameter |
| US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| US4910300A (en) | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
| US5338532A (en) | 1986-08-18 | 1994-08-16 | The Dow Chemical Company | Starburst conjugates |
| US6312679B1 (en) | 1986-08-18 | 2001-11-06 | The Dow Chemical Company | Dense star polymer conjugates as dyes |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| KR970005898B1 (ko) | 1987-09-21 | 1997-04-21 | 젠- 프로우브 인코퍼레이티드 | 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약 |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| US5460831A (en) | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| DE69431669T2 (de) | 1993-09-02 | 2003-10-23 | Ribozyme Pharmaceuticals, Inc. | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| CA2256449A1 (en) | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies |
| DE69819150T3 (de) | 1997-06-06 | 2007-12-20 | Dynavax Technologies Corp., San Diego | Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| CN1358171A (zh) | 1999-06-08 | 2002-07-10 | 拉卓拉药物公司 | 包含氨基氧基的化合价平台分子 |
| EP1420829A4 (en) * | 2001-08-07 | 2006-05-17 | Dynavax Tech Corp | IMMUNOMODULATING COMPOSITIONS, FORMULATIONS AND METHOD FOR THEIR USE |
| WO2003086280A2 (en) | 2002-04-04 | 2003-10-23 | Coley Pharmaceutical Gmbh | Immunostimulatory g,u-containing oligoribonucleotides |
| ATE477000T1 (de) * | 2002-11-21 | 2010-08-15 | Bayhill Therapeutics Inc | Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| EP1599726A4 (en) | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY |
| AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| WO2005097993A2 (en) | 2004-02-19 | 2005-10-20 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| WO2006028742A2 (en) | 2004-09-01 | 2006-03-16 | Dynavax Technologies Corporation | Methods and conpositions for inhibition of innate immune responses and autoimmunity |
| US20100113565A1 (en) | 2004-12-08 | 2010-05-06 | Gorden Keith B | Immunostimulatory combinations and methods |
| EP1836218A2 (en) | 2004-12-17 | 2007-09-26 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| JP2008531502A (ja) | 2005-02-22 | 2008-08-14 | ザ レジェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 胃腸の炎症を処置する方法 |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| EP1924284A1 (en) | 2005-09-14 | 2008-05-28 | Hartmann, Gunther | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides |
| JP2009511034A (ja) | 2005-10-12 | 2009-03-19 | キャンサー・リサーチ・テクノロジー・リミテッド | 免疫異常を治療するための方法および組成物 |
| CN102517292B (zh) | 2005-11-25 | 2014-12-24 | 佐蒂斯比利时股份有限公司 | 免疫刺激性寡核糖核苷酸 |
| EP2021008B1 (en) * | 2006-04-07 | 2015-12-02 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 |
| US20080026986A1 (en) | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
| AU2007284036A1 (en) | 2006-08-16 | 2008-02-21 | Protiva Biotherapeutics, Inc. | Nucleic acid modulation of Toll-like receptor-mediated immune stimulation |
| EP2357231A2 (en) | 2007-07-09 | 2011-08-17 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds |
| EP2361980B1 (en) | 2007-10-26 | 2016-12-07 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| WO2009154610A1 (en) | 2008-06-17 | 2009-12-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| US20100047188A1 (en) | 2008-08-04 | 2010-02-25 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| US8940310B2 (en) | 2010-06-16 | 2015-01-27 | Dynavax Technologies Corporation | Methods of treatment using TLR7 and/or TLR9 inhibitors |
| JP5921535B2 (ja) | 2010-06-16 | 2016-05-24 | ディナバックス テクノロジーズ コーポレイション | Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法 |
| US9063123B2 (en) | 2011-03-29 | 2015-06-23 | Dynavax Technologies Corporation | Transgenic mice expressing human toll-like receptor 8 |
-
2013
- 2013-03-15 US US13/842,861 patent/US9228184B2/en active Active
- 2013-04-02 AU AU2013202255A patent/AU2013202255B2/en not_active Ceased
- 2013-09-27 JP JP2015534781A patent/JP6395266B2/ja active Active
- 2013-09-27 CN CN201380050891.5A patent/CN104937102A/zh active Pending
- 2013-09-27 CA CA2886755A patent/CA2886755A1/en active Pending
- 2013-09-27 WO PCT/US2013/062479 patent/WO2014052931A1/en not_active Ceased
- 2013-09-27 EP EP13773582.5A patent/EP2900823B1/en active Active